Open access · CC-BY
via OpenAlex
End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies
Richard Venz, Tina Pekeč, Iskra Katic, Rafal Ciosk, Collin Y. Ewald
eLife · 2021 · ▲ 65 citations
Abstract
Abstract Preferably, lifespan-extending therapies should work when applied late in life without causing undesired pathologies. However, identifying lifespan-extending interventions that are effective late in life and which avoid undesired secondary pathologies remains elusive. Reducing Insulin/IGF-1 signaling (IIS) increases lifespan across species, but the effects of reduced IIS interventions in extreme geriatric ages remains unknown. Using the nematode C. elegans , we engineered the conditional depletion of the DAF-2/insulin/IGF-1 transmembrane receptor using an auxin-inducible degradation (AID) system that allows for the temporal and spatial reduction in DAF-2 protein levels at time points after which interventions such as RNAi may lose efficacy. Using this system, we found that AID-mediated depletion of DAF-2 protein efficiently extends animal lifespan. Depletion of DAF-2 during early adulthood resulted in multiple adverse phenotypes, including growth retardation, germline shrinkage, egg-retention, and reducing offspring. By contrast, however, AID-mediated depletion of DAF-2 specifically in the intestine resulted in an extension of lifespan without these deleterious effects. Importantly, AID-mediated depletion of DAF-2 protein in animals past their median lifespan allowed for an extension of lifespan without affecting growth or behavioral capacity. Thus, both late-in-life targeting and tissue-specific targeting of IIS minimize the deleterious effects typically seen with interventions that reduced IIS, suggesting potential therapeutic methods by which longevity and healthspan(definition) can be increased in even geriatric populations.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.7554/elife.71335
- Canonical
- link ↗
- Fetched
- 2026-10-22 MST
Cite this
APA
Venz, R., Pekeč, T., Katic, I., Ciosk, R., & Ewald, C.Y. (2021). End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies. <em>eLife</em>. https://doi.org/10.7554/elife.71335
Vancouver
Venz R, Pekeč T, Katic I, Ciosk R, Ewald CY. End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies. eLife. 2021. doi:10.7554/elife.71335.
BibTeX
@article{richard2021Endofl,
title = {End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies},
author = {Richard Venz and Tina Pekeč and Iskra Katic and Rafal Ciosk and Collin Y. Ewald},
journal = {eLife},
year = {2021},
doi = {10.7554/elife.71335},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
bioRxiv (Cold Spring Harbor Laboratory) 2026
Preprint · CC-BY
Strong inhibition of insulin/IGF-1 signaling in early-mid adulthood compresses morbidity, but in later life accelerates aging
2026
Preprint
Strong inhibition of insulin/IGF-1 signaling in early-mid adulthood compresses morbidity, but in later life accelerates aging
Nature Communications 2022
Open access · CC-BY
Intestine-specific removal of DAF-2 nearly doubles lifespan in Caenorhabditis elegans with little fitness cost
Aging Cell 2016
Open access · CC-BY
Comparative idiosyncrasies in life extension by reduced mTOR signalling and its distinctiveness from dietary restriction
Nature Communications 2021
Open access · CC-BY
A PTEN variant uncouples longevity from impaired fitness in Caenorhabditis elegans with reduced insulin/IGF-1 signaling
Aging cell 2026
Open access · OA